Tesla (NASDAQ:TSLA): Jefferies raised its price target for Tesla to $210 from $160 after increasing its third-quarter Model S delivery estimate from 5,250 units to 5,500 units. The firm believes the Model S fire last week underscores the vehicle’s safety, and the analyst keeps a Buy rating on Tesla.
Biogen (NASDAQ:BIIB): Leerink Swann reports that experts expect Biogen’s Tecfidera drug to be made available in the European Union, since industry experts have observed that patients there are very eager to obtain the drug. The firm raised its price target on the stock to $300 from $286 and keeps an Outperform rating on the shares.
Akamai (NASDAQ:AKAM): Pacific Crest believes that year-over-year Internet media growth accelerated to roughly 50 percent last month, up from the mid-40 percent range in August, leading the firm to predict that Akamai ‘s third-quarter results will surpass expectations. The firm also expects the company to provide stronger-than-expected fourth-quarter guidance, and it predicts the stock could reach the mid-$50s. However, the firm keeps a Sector Perform rating on the stock.
Outerwall (NASDAQ:OUTR): Monness Crespi reiterated its Sell rating on Outerwall, believing that the DVD rental addressable market is in irreversible decline and that Redbox is worth $30 to $35 at most.